Opdualag (nivolumab/relatlimab-rmbw)

P2, N=260, Not yet recruiting, Bristol-Myers Squibb

P4, N=30, Not yet recruiting, Bristol-Myers Squibb

P1, N=110, Active, not recruiting, Universitair Ziekenhuis Brussel | Phase classification: P1/2 --> P1

P1/2, N=62, Recruiting, Bristol-Myers Squibb Services Unlimited Company

P2, N=20, Active, not recruiting, Melanoma Institute Australia | Trial completion date: Jan 2036 --> Oct 2035

P1/2, N=15, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting

P2, N=90, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jul 2027 --> Nov 2028 | Trial primary completion date: Jul 2027 --> Nov 2028

P2, N=105, Recruiting, NYU Langone Health | N=69 --> 105 | Trial completion date: Dec 2025 --> Feb 2028 | Trial primary completion date: Jun 2025 --> Aug 2026

We present the case of an 81-year-old male with a history of recurrent metastatic melanoma previously treated with nivolumab and relatlimab (Opdualag), who developed a persistent pruritic eruption following initiation of dual PD-1/LAG-3 blockade. Despite discontinuation of immunotherapy six months before dermatologic evaluation and use of multiple topical corticosteroids and oral antihistamines, symptoms persisted...At follow-up, the patient reported persistent activity, receiving intramuscular triamcinolone acetonide and adjunctive therapies, including hydroxyzine, hydrocortisone 2.5% cream (for groin), and triamcinolone 0.1% ointment...This case illustrates the diagnostic and therapeutic challenges in managing ICI-induced BP and highlights the early course of dupilumab therapy, which had not yet produced clinical improvement at the time of last follow-up. Continued therapy was planned, and no adverse effects were reported.

P1/2, N=15, Not yet recruiting, University of Wisconsin, Madison

P1/2, N=24, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed